What can we help you find?

September 10, 2012 6:00 pm ET

Merck & Co., Inc. priced today a $2.5 billion public offering of senior
unsecured notes. The notes include:

Proceeds from the notes will be used for general corporate purposes,
including without limitation making contributions to our pension plans
and repayment of outstanding commercial paper borrowings and upcoming
debt maturities. The offering is expected to close on Sept. 13, 2012,
subject to customary closing conditions. Citigroup Global Markets Inc.,
J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith
Incorporated are acting as joint book-running managers for the offering.

This release does not constitute an offer to sell or a solicitation of
an offer to buy the securities described herein, nor shall there be any
sale of these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction. The
offering may be made only by means of a prospectus supplement and
accompanying base prospectus. When available, copies of the prospectus
supplement and accompanying base prospectus related to the offering may
be obtained from Citigroup Global Markets Inc. toll-free at
1-877-858-5407, J.P. Morgan Securities LLC collect at 1-212-834-4533 or
at Merrill Lynch, Pierce, Fenner & Smith Incorporated toll-free at
1-800-294-1322.

About Merck

Today’s Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies, and
consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships.

Forward Looking Statement

This news release includes “forward-looking statements” within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Such statements may include,
but are not limited to, Merck’s ability to complete the offering and
Merck’s expectations for the use of proceeds from the offering. Such
statements are based upon the current beliefs and expectations of
Merck’s management and are subject to significant risks and
uncertainties. Actual results may differ from those set forth in the
forward-looking statements.

The following factors, among others, could cause actual results to
differ from those set forth in the forward-looking statements: the
possibility that the expected synergies from the merger of Merck and
Schering-Plough will not be realized, or will not be realized within the
expected time period; the impact of pharmaceutical industry regulation
and health care legislation; the risk that the businesses will not be
integrated successfully; disruption from the merger making it more
difficult to maintain business and operational relationships; Merck’s
ability to accurately predict future market conditions; dependence on
the effectiveness of Merck’s patents and other protections for
innovative products; the risk of new and changing regulation and health
policies in the U.S. and internationally and the exposure to litigation
and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in Merck’s 2011 Annual Report on Form 10-K and the company’s other
filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (www.sec.gov).

Merck & Co., Inc.
Media :
Steve Cragle, 908-423-3461
or
Investor:
Carol Ferguson, 908-423-4465